Psilocybin and classical psychedelics raise blood pressure and heart rate substantially across the entire session. Hutten and colleagues (2019) documented systolic increases of 10 to 20 mmHg and heart rate increases of 20 to 30 BPM during peak effects. Uncontrolled hypertension, structural heart disease, recent cardiac events, and significant arrhythmia are exclusion criteria across every major clinical trial.
If you are 40 or older, have a cardiac diagnosis, or take any antihypertensive medication, a session belongs after cardiology clearance, not before. This article is educational and is not medical advice. Speak with your cardiologist and prescribing physician before any psychedelic decision.
The cardiovascular safety profile of psilocybin is the second most preventable harm category in psychedelic-assisted therapy, after the lithium interaction, and the population most at risk is also the population currently most attracted to retreats. Founders, executives, and high-functioning professionals in their forties and fifties read the Johns Hopkins and COMPASS Pathways headlines, hear about retreat options, and book sessions without flagging that they are at the peak of the cardiovascular risk window. Hutten and colleagues (2019, ACS Chemical Neuroscience) documented that an oral psilocybin session raises systolic blood pressure by approximately 10 to 20 mmHg and heart rate by 20 to 30 beats per minute, with effects sustained across the 4 to 6 hour session window. This is not a brief autonomic spike. It is a multi-hour cardiovascular load.
The other cardiovascular question, and the one that almost no retreat operator can answer competently, is the 5-HT2B receptor concern. Classical psychedelics including psilocybin, psilocin, LSD, and DMT bind not only their primary 5-HT2A target but also the 5-HT2B receptor, which is the established mechanism behind drug-induced valvular heart disease. The precedent comes from fenfluramine, the appetite suppressant withdrawn in 1997, and pergolide, the Parkinson medication withdrawn in 2007, both pulled from market because chronic 5-HT2B agonism produced cardiac valve fibrosis and regurgitation in long-term users.
This piece walks through the acute cardiovascular response during a session, the 5-HT2B valve question and what it does and does not mean for therapeutic dosing, why every clinical trial uses hypertension as an exclusion criterion, the specific issues with beta-blockers and other heart medications, and a practical cardiac screening protocol for any 40+ patient considering a session. The article is meant for educated patients, the cardiologists who clear them, and the practitioners who screen them. It is not a substitute for direct medical care.
- Hutten et al. (2019) documented psilocybin sessions raise systolic blood pressure by 10 to 20 mmHg and heart rate by 20 to 30 BPM, sustained across the 4 to 6 hour session window.
- Classical psychedelics activate 5-HT2B alongside their primary 5-HT2A target, the receptor implicated in fenfluramine and pergolide valvulopathy withdrawals.
- Nichols (2017, ACS Chemical Neuroscience) concluded that infrequent therapeutic dosing of 1 to 3 sessions per year does not match the chronic-exposure pattern that drove the valvulopathy precedent, but daily microdosing protocols over months do raise legitimate concern.
- COMPASS Pathways COMP360, MAPS Phase 3, and the Johns Hopkins psilocybin trials all list uncontrolled hypertension (typically above 140 over 90) as a hard exclusion criterion.
- Beta-blockers blunt the psychedelic experience by reducing sympathetic tone and have direct 5-HT receptor activity. Anticoagulants, digoxin, and other cardiac medications require coordinated cardiology clearance.
- 40+ executive demographics sit at peak cardiovascular risk and the highest probability of being on antihypertensives. Honest disclosure during screening is non-negotiable.
What Happens to Blood Pressure and Heart Rate During a Session?
The acute cardiovascular response to psilocybin is consistent, measurable, and sustained for the full duration of the experience. Hutten and colleagues (2019, ACS Chemical Neuroscience) reported that oral psilocybin at typical therapeutic doses of 20 to 30 milligrams produces a systolic blood pressure increase of approximately 10 to 20 mmHg, a diastolic increase of roughly 5 to 10 mmHg, and a heart rate increase of 20 to 30 beats per minute. The peak response generally occurs 60 to 120 minutes after dosing and the elevation remains present until the experience fades around the 4 to 6 hour mark.
The clinical implication is straightforward when you do the arithmetic. A 50 year old founder with a resting baseline of 135 over 85, which is the high end of what most internists treat as borderline, will spend several hours of the session in the 150 to 165 systolic range. A patient with controlled stage one hypertension at 145 over 92 on stable medication will see readings climb into 160 to 170 territory. This is not a single transient spike. It is a multi-hour pressure load on the same cardiovascular system that is already operating at the upper end of its design envelope.
The autonomic mechanism behind the response is well characterized. 5-HT2A agonism on cortical pyramidal neurons drives widespread excitation that propagates to the brainstem cardiovascular control centers, increasing sympathetic outflow and reducing parasympathetic tone. The result is the same pressure-rate signature you would see during sustained moderate-intensity exercise, except the patient is lying still in a session room rather than burning the metabolic load through muscular work. The mismatch between sympathetic drive and physical activity is part of why the response feels intense subjectively.
Hutten, Mason, Dolder, and Kuypers (2019), publishing in ACS Chemical Neuroscience, documented the cardiovascular pharmacodynamics of oral psilocybin at therapeutic doses of 20 to 30 milligrams. Systolic blood pressure rose by approximately 10 to 20 mmHg, diastolic by 5 to 10 mmHg, and heart rate by 20 to 30 BPM, with peak response occurring 60 to 120 minutes after dosing. The mechanism is sympathetic nervous system activation driven by 5-HT2A agonism, not a direct vasoconstrictive effect. The cardiovascular elevation remained present across the entire 4 to 6 hour psychoactive window rather than resolving at peak. The response is consistent across studies and forms the empirical basis for the uncontrolled-hypertension exclusion criteria adopted by every major clinical psilocybin trial, including COMPASS COMP360 and the Johns Hopkins program.
How Does the 5-HT2B Receptor Concern Affect Valve Risk?
The 5-HT2B serotonin receptor sits at the center of the most consequential pharmacology debate in modern psychedelic medicine, and the precedent comes from drugs that are no longer on the market. Both fenfluramine, the appetite suppressant in the Fen-Phen combination withdrawn by the FDA in 1997, and pergolide, the dopamine agonist withdrawn in 2007, were pulled because chronic 5-HT2B agonism produced cardiac valve fibrosis, regurgitation, and clinically significant valvulopathy across thousands of long-term users. The mechanism is well established: 5-HT2B activation on cardiac valve fibroblasts drives proliferation and extracellular matrix deposition that thickens and stiffens valve leaflets over time.
Classical psychedelics bind 5-HT2B with measurable affinity. Nichols (2017, ACS Chemical Neuroscience) reviewed the receptor binding profile of psilocin, LSD, DMT, and related compounds and concluded that 5-HT2B affinity is real but that the clinical concern depends almost entirely on exposure pattern. The fenfluramine and pergolide cases involved daily dosing across months and years, producing chronic continuous receptor activation. Therapeutic psilocybin dosing in the 1 to 3 sessions per year range does not approximate that exposure pattern, and Nichols concluded that the valvulopathy concern is unlikely to materialize at infrequent therapeutic intervals.
The concern becomes mechanistically plausible in two different scenarios. The first is daily microdosing protocols sustained over many months, where the cumulative 5-HT2B exposure begins to look more like the fenfluramine pattern than the therapeutic session pattern. The second is patients with pre-existing valve pathology, genetic predispositions to fibrotic disease, or other risk factors that lower the threshold at which 5-HT2B agonism produces clinical harm. For these specific populations the screening question is not academic.
What the Fenfluramine Precedent Actually Showed
The fenfluramine valvulopathy data is worth understanding because it sets the prior for how seriously to take the 5-HT2B question. Across the late 1990s post-withdrawal analyses, roughly 20 to 30 percent of patients who took fenfluramine for more than 4 to 6 months developed echocardiographic evidence of valve regurgitation, with a meaningful minority progressing to clinically significant valve disease requiring surgery. The dose-response was clear: longer exposure and higher cumulative dose produced worse outcomes. The mechanism implicated 5-HT2B specifically because in vitro receptor pharmacology and animal models converged on the same target.
The translation to psychedelic dosing is not direct. A patient doing 2 psilocybin sessions per year experiences acute 5-HT2B activation for roughly 8 to 12 hours total annually. A patient on daily microdosing at 100 micrograms of LSD or 100 milligrams of psilocybin material experiences sustained low-level 5-HT2B activation for many hours every day. The chronic exposure case looks much more like fenfluramine than the therapeutic session case does, and the absence of long-term echocardiographic surveillance data on heavy microdosers is the open question the field has not yet answered.
Why Do Clinical Trials Exclude Hypertensive Patients?
The exclusion of uncontrolled hypertension across the psychedelic clinical trial landscape is the most consistent single inclusion criterion after the lithium and bipolar exclusions. The COMPASS Pathways COMP360 program, the MAPS Phase 3 MDMA-AT protocol (Mitchell et al., 2021, Nature Medicine), and every Johns Hopkins and Imperial College psilocybin trial list resting blood pressure above approximately 140 over 90 on screening day as an exclusion criterion, with stricter cutoffs for patients with documented cardiovascular disease. The threshold is not arbitrary. It is the point at which the predictable session-driven pressure surge becomes clinically dangerous.
The logic is simple arithmetic. A patient at 140 over 90 baseline who experiences a 15 mmHg systolic increase during a session will spend hours at 155 over 95 or higher. That is the territory where hypertensive urgency becomes a real consideration, where the risk of plaque rupture in patients with subclinical coronary disease rises measurably, and where the cerebrovascular stroke risk in patients with undiagnosed aneurysms or arteriovenous malformations is no longer trivial. The exclusion exists because the cumulative probability of an adverse event crosses an unacceptable line.
The patient with well-controlled hypertension on stable medication, with normal echocardiography and a recent stress test, is a different case from the patient with uncontrolled or undiagnosed hypertension. The first patient may qualify for a session after cardiology clearance and careful selection of which antihypertensives are continued through the session window. The second patient does not qualify for anything until the underlying cardiovascular picture is properly evaluated. Retreat operators conflating these two cases is the single most common cardiac safety failure I see in preparation consultations.
What Cardiology Clearance Should Actually Cover
A meaningful cardiology clearance for psychedelic-assisted therapy is not a single office blood pressure reading. It should include 24 hour ambulatory blood pressure monitoring to capture the true resting profile, a recent ECG to rule out conduction abnormalities and silent ischemia, an echocardiogram for any patient over 50 or with known risk factors, and a stress test if there is any history suggestive of coronary disease. The clearance letter from the cardiologist should specifically address the session-day medication plan, the resting blood pressure target, and the criteria under which the session would be cancelled.
"The most preventable cardiac harm in this work is the founder who skips the cardiology conversation because nothing has ever hurt yet. The session does not care that you have been asymptomatic. The pressure load is the same whether the underlying disease is known or not."
How Do Beta-Blockers and Heart Medications Interact?
Cardiac medications interact with psilocybin in different ways depending on the class, and beta-blockers are the most clinically relevant case because they sit at the intersection of two distinct mechanisms. Beta-blockers reduce the sympathetic nervous system response that drives the session-driven blood pressure and heart rate elevation, which blunts the cardiovascular surge but also dampens the autonomic intensity that contributes to the subjective psychedelic experience. Propranolol specifically also has direct 5-HT receptor activity and can attenuate the serotonergic signal at the receptor level, producing a more pronounced reduction in psychedelic experience intensity.
The clinical implication is that beta-blockers create a screening dilemma. A patient on a beta-blocker for essential hypertension may be able to switch to an ACE inhibitor or angiotensin receptor blocker for the session window, since those drug classes do not interfere with autonomic response or 5-HT signaling. A patient on a beta-blocker for atrial fibrillation rate control, post-myocardial infarction cardioprotection, or hypertrophic cardiomyopathy generally cannot safely switch, and the underlying indication often means a psychedelic session is not appropriate at that point in the cardiac history.
Other cardiac medications carry their own considerations. Anticoagulants including warfarin, apixaban, and rivaroxaban require careful coordination because the session-driven blood pressure surge theoretically elevates hemorrhagic risk in patients with cerebrovascular disease or recent procedures. Digoxin, used for rate control in atrial fibrillation and in certain heart failure phenotypes, has a narrow therapeutic window and is sensitive to autonomic shifts and electrolyte changes. ACE inhibitors and angiotensin receptor blockers are generally more compatible than beta-blockers because they do not interfere with the autonomic response, though baseline blood pressure control remains the gating question.
| Medication class | Interaction with psilocybin session | Screening implication |
|---|---|---|
| Beta-blockers | Blunts effects Reduces sympathetic surge and may attenuate subjective experience. Propranolol has direct 5-HT receptor activity. | Cardiology decision. Switchable for essential hypertension. Often non-negotiable for arrhythmia or post-MI indications. |
| ACE inhibitors / ARBs | Generally compatible Does not interfere with autonomic response or 5-HT signaling. | Baseline BP control remains the gating question. Stable medication typically continued through session window. |
| Anticoagulants | Coordination required Session-driven BP surge theoretically elevates hemorrhagic risk in patients with cerebrovascular disease. | Cardiology clearance with attention to underlying indication and recent procedures. |
| Digoxin | High-risk interaction Narrow therapeutic window. Sensitive to autonomic shifts and electrolyte changes. | Generally inappropriate without specialized cardiology supervision. Underlying indication often itself excludes a session. |
| Calcium channel blockers | Generally compatible May actually buffer the session-driven pressure surge. | Typically continued through session window. Confirms baseline BP control. |
The matrix is not exhaustive and individual cases require individualized assessment. The principle is that any cardiac medication requires the prescribing cardiologist to be in the loop, and a retreat operator without that infrastructure is not the appropriate venue for any patient with a meaningful cardiac history. The session-day medication plan, the resting blood pressure target, and the cancellation criteria should all be defined in writing before the session date is scheduled.
The 40+ Founder Demographic Carries Specific Risk Factors
The cardiovascular risk profile of the 40+ executive demographic is the central reason this article exists, because the population most attracted to psychedelic-assisted therapy is also the population at peak cardiovascular risk. By age 45, the American Heart Association reports that approximately 47 percent of US adults meet the diagnostic criteria for hypertension under the 2017 ACC/AHA guidelines, and a substantial fraction are either undiagnosed or on antihypertensive medication without realizing it complicates psychedelic safety. The age 40 to 65 window is also when subclinical coronary disease, paroxysmal arrhythmia, and undiagnosed valve pathology cluster.
The demographic risk is compounded by behavioral patterns specific to high-functioning executives. The founder who has not seen a primary care physician in three years because the company comes first is the same founder who books a psilocybin retreat after reading a Tim Ferriss interview. The intake form asks about cardiac history. The patient checks no because no event has happened yet, not because the screening has been done. The retreat coordinator without cardiology training accepts the disclosure at face value, and the session goes ahead without ambulatory blood pressure data, without an ECG, and without a baseline echocardiogram.
The other piece of the demographic picture is the medication-disclosure gap. A founder on lisinopril for borderline hypertension may not think of it as a cardiac medication because the primary care doctor framed it as routine. A patient on low-dose aspirin after a brief consultation with a cardiologist five years ago may not list it on the intake form. A patient on a beta-blocker prescribed by an internist for situational anxiety rather than cardiac indication may not connect it to the screening question. The cumulative effect is that a substantial fraction of the highest-cardiovascular-risk population presents to retreats with incomplete disclosure, not because of deception but because the screening framing does not reach the relevant facts.
The American Heart Association reports that approximately 47 percent of US adults meet the 2017 ACC/AHA criteria for hypertension, defined as resting blood pressure above 130 over 80, with prevalence rising sharply across the 40 to 65 age window. The same demographic shows clustering of subclinical coronary disease, paroxysmal atrial fibrillation, and undiagnosed valve pathology including mitral regurgitation and aortic sclerosis. The psychedelic-curious founder population sits at the center of this risk window, often on antihypertensive medication such as lisinopril or amlodipine, frequently without a recent cardiology evaluation or ambulatory blood pressure profile. The screening gap is not patient deception. It is a structural mismatch between retreat intake framing and the cardiology-relevant facts that actually predict session-day safety.
What Does a Real Cardiac Screening Protocol Look Like?
The cardiac screening that any 40+ patient considering a psilocybin session should complete before scheduling looks substantially different from what most retreat intake forms request. A minimum responsible screening package includes a recent primary care evaluation within the past 12 months, an ECG within the past 6 months, ambulatory or home blood pressure monitoring over at least 7 days, a baseline echocardiogram for patients over 50 or with risk factors, and a written clearance letter from the prescribing cardiologist if any cardiac medication or diagnosis is present. This is not an elaborate protocol. It is the minimum the available pharmacology evidence supports.
The ambulatory or home blood pressure monitoring step is the one most commonly skipped, and it is also the most informative. Office blood pressure readings systematically underestimate true cardiovascular load because of white-coat effects and because a single reading captures one moment rather than the daily profile. A founder with a 130 over 80 office reading and a 145 over 92 home morning average is a different patient than the office reading alone suggests, and the session-driven surge in the second case carries meaningfully higher risk than in the first. Seven days of morning and evening home readings, recorded properly, is the cheapest single high-value addition to the standard screening.
The cardiology clearance letter, when one is required, should specifically address four points. First, the resting blood pressure threshold above which the session should be cancelled on the day. Second, the session-day medication plan, including which antihypertensives are continued and which are temporarily held. Third, the on-site monitoring requirement, including baseline vitals, peak-effect vitals, and post-session check intervals. Fourth, the criteria for medical escalation during the session, including the threshold for emergency department referral. A retreat operator that cannot accommodate these requirements is not the right venue for a patient with a meaningful cardiac history.
The Direct Access Cardiac Screening Position
The screening position I use in preparation consultations treats any 40+ patient with even borderline cardiac history as automatically requiring cardiology clearance before a session is on the calendar. The conversation is not "do you feel cardiovascularly healthy" but "what does your most recent ambulatory blood pressure monitoring show, when was your last ECG, and who is your prescribing cardiologist." If the answers reveal gaps, the appropriate response is to pause session planning and route the patient to their primary care physician first, then to cardiology if indicated. Saying not yet is part of the work. For preparation flow once the cardiac picture is cleared, see the psilocybin therapy preparation piece. For the parallel bipolar question, the bipolar screening framework covers the affective side of the same screening burden.
A minimum cardiac screening package for any 40+ patient considering psilocybin includes primary care evaluation within 12 months, a 12-lead ECG within 6 months to rule out conduction abnormalities and silent ischemia, ambulatory or home blood pressure monitoring across 7 days with morning and evening readings, baseline echocardiogram for patients over 50 or with risk factors, and written cardiology clearance if any cardiac medication or diagnosis is present. The session-day medication plan, the resting BP cancellation threshold (typically 140 over 90), the on-site monitoring protocol covering baseline and peak-effect vitals, and the medical escalation criteria including emergency department referral thresholds should all be defined in writing before any session date is scheduled. This is the minimum the available pharmacology evidence supports, not an elaborate addition.